Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

AC Immune (ACIU) EPS (Weighted Average and Diluted) (2015 - 2022)

AC Immune (ACIU) reported EPS (Weighted Average and Diluted) of $1942.6 for Q1 2022, down 86.82% year-over-year from $14742.7 in Q1 2021, and down 86.82% on a QoQ basis from $14742.7 in Q1 2021.

AC Immune (ACIU) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at $1942.6 in Q1 2022.

  • Quarterly EPS (Weighted Average and Diluted) fell 86.82% year-over-year to $1942.6 in Q1 2022, while the trailing twelve-month figure through Sep 2019 was $19796.7 (changed N/A YoY) and the FY2025 annual result came in at -$0.84, down 45.02% from the prior year.
  • EPS (Weighted Average and Diluted) retreated to $1942.6 in Q1 2022 per ACIU's latest filing, from $14742.7 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $19796.7 in Q3 2019 and bottomed at -$25222.4 in Q2 2019.
  • The 3-year median for EPS (Weighted Average and Diluted) is $8342.6 (2021), against an average of $2814.9.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 86.82% in 2022, while the deepest fall reached 86.82% in 2022.
  • Tracing ACIU's EPS (Weighted Average and Diluted) over 3 years: stood at $19796.7 in 2019, then decreased by 25.53% to $14742.7 in 2021, then slumped by 86.82% to $1942.6 in 2022.
  • Per Business Quant, the three latest ACIU EPS (Weighted Average and Diluted) figures stand at $1942.6 (Q1 2022), $14742.7 (Q1 2021), and $19796.7 (Q3 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 AC Immune 325.88 Mn 211.53 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 1,942.56
Mar 31, 2021 14,742.66
Sep 30, 2019 19,796.74
Jun 30, 2019 -25,222.39
Dec 31, 2017 0.07
Dec 31, 2016 -0.10
Jun 30, 2016 0.05
Dec 31, 2015 -0.12